{"url_path":"/sec/pvla/8-k/2026-06-30/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 ** **         Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1583648/0001104659-26-079087-index.html","accession_number":"0001104659-26-079087","cik":"0001583648","ticker":"PVLA","issuer_name":"PALVELLA THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1583648/0001104659-26-079087-index.html","primary_entity_key":"0001583648","primary_entity_name":"PALVELLA THERAPEUTICS, INC."},"word_count":647,"has_tables":true,"body_markdown":"**Item 5.02** **         Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\nOn June 29, 2026 (the “Appointment Date”), the Board of\nDirectors (the “Board”) of Palvella Therapeutics, Inc. (the “Company”) increased the size of the Board from seven\nto eight members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed Matthew Pauls, to serve as a\nClass I director, with an initial term expiring at the Company’s 2027 Annual Meeting of Stockholders.\n\n \n\nMr. Pauls, 56, currently serves as the Chief Executive Officer of Savara,\nInc. (NASDAQ: SVRA) (“Savara”), a public clinical-stage biopharmaceutical company focused on rare respiratory diseases, a\nrole he has held since December 2020. Prior to Savara, Mr. Pauls served as President and Chief Executive Officer of Strongbridge Biopharma\nplc (“Strongbridge”), a public biopharmaceutical company focused on rare respiratory diseases, which was acquired by Xeris\nPharmaceuticals, Inc. At Strongbridge, he led the company through its Nasdaq initial public offering, oversaw the successful commercialization\nof KEVEYIS® and Macrilen®, and advanced RECORLEV® through pivotal Phase 3 development for Cushing’s syndrome. Earlier\nin his career, Mr. Pauls was Chief Commercial Officer of Insmed, Inc., where he led global commercial and technical operations, and held\nsenior leadership roles at Shire Pharmaceuticals Group Plc, Bristol-Myers Squibb Company, and Johnson & Johnson Services, Inc. Mr.\nPauls has served as a member of Savara’s board of directors since April 2017 and as chair of Savara’s board since September\n2020. Mr. Pauls currently serves as a member of the board of directors of Pelthos Therapeutics Inc. (NYSE American: PTHS), a public commercial-stage\nbiopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products, a role\nhe has held since April 2024 and Atsena Therapeutics Inc., a private clinical-stage gene therapy company focused on inherited retinal\ndiseases that cause blindness, a role he has held since May 2026. Additionally, Mr. Pauls previously served on the board of directors\nof Soleno Therapeutics, Inc. from 2023 to 2026, including as Lead Independent Director from 2024 until its $2.9 billion acquisition by\nNeurocrine Biosciences in 2026. During his tenure, Soleno secured FDA approval and successfully launched VYKAT™ XR, the first and\nonly FDA-approved treatment for hyperphagia in patients with Prader-Willi syndrome, a serious, rare genetic disease. Mr. Pauls also previously\nserved on the board of directors of Amplo Biotechnology and Zyla Life Sciences, LLC and as Chair of the Board of Directors of Mast Therapeutics,\nInc. Mr. Pauls holds a B.S. and an M.B.A. from Central Michigan University and a J.D. from Michigan State University College of Law.\n\n \n\nIn accordance with the Company’s Non-Employee Director Compensation\nPolicy, as amended from time to time (the “Director Compensation Policy”), the Company will pay Mr. Pauls an annual retainer\nfor his service on the Board and, if applicable, committees thereof. In addition, on the Appointment Date, pursuant to the Director Compensation\nPolicy, Mr. Pauls was granted an option to purchase 6,000 shares of the Company’s common stock, par value $0.001 per share, which\nvests in equal monthly installments over thirty-six months, subject to continued service.\n\n \n\nThere are no arrangements or understandings between Mr. Pauls and any\nother person pursuant to which he was selected as a director. There are no related party transactions between the Company and Mr. Pauls\n(or any of his immediate family members) requiring disclosure under Item 404(a) of Regulation S-K. Mr. Pauls does not have any family\nrelationships with any of the Company’s directors or executive officers. The Board has determined that Mr. Pauls is independent\nin accordance with the applicable Nasdaq listing rules. \n\n \n\n****\n\n \n\n \n\n**** \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n \n \n**PALVELLA THERAPEUTICS, INC.**\n\n \n \n \n \n\nDate:\nJune 30, 2026\nBy: \n/s/ Matthew Korenberg\n\n \n \n \nMatthew Korenberg\n\n \n \n \n*Chief Financial Officer*"}